Ripple CTO Emeritus David Schwartz expressed concern that heavy content filtering on social media could hide posts warning about XRP scams, potentially reducing scam awareness. In 2025, U.S. consumers reported $2.1 billion in losses from scams that started on social media, with investment scams accounting for $1.1 billion. Schwartz prefers lighter filtering to monitor false claims, though it's unclear if this approach reduces scam losses. The data highlights the challenge of balancing content moderation and scam prevention on social platforms.
XRP scam warnings and social media filtering provide context for Pluang's market data. As of Oct 27, 2026 07:02 WIB, 28 of 50 major cryptocurrencies rose while 20 fell. Notable movers include COMP at Rp396.312 with a 3.48% increase and 100% sell order activity, UNI at Rp128.848 up 3.30% with 63% buy orders, and ENJ at Rp456 rising 2.94% with 69% buy orders.
Monteverde & Associates PC is investigating the fairness of proposed mergers involving Synaptics (SYNA), Eagle Financial Services (EFSI), Victory Capital Holdings (VCTR), and Centerspace (CSR). Shareholders are urged to consider if the deals are fair...
At the Cisco Partner Summit 2026, Presidio was honored as the Global Innovation Partner of the Year, recognizing its outstanding innovation and success in delivering impactful customer solutions. This award highlights Presidio's commitment to partner...
Presidio was awarded the Global Services and Software Excellence Partner of the Year at the Cisco Partner Summit 2026. This award recognizes Presidio's outstanding innovation and success in delivering solutions that help customers achieve meaningful ...
Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...
Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...
